Drug Trial Radar · NCT00658632
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Last checked: Nov 20, 2026Latest source record: May 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,397
Actual
Start
Feb 2008
Primary completion
Apr 2009
Study completion Sep 2009
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Apr 15, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the efficacy and safety of Rabeprazole (RAB) Extended-Release (ER) 50 mg versus Esomeprazole (ESO) 40 mg in subjects with erosive gastroesophageal reflux disease (eGERD).
Conditions
- Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodiumDrug
Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
EsomeprazoleDrug
Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 WeeksTime frame: Baseline and Week 8
- Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 WeeksTime frame: Baseline and Week 4
Locations
85 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Huntsville, Alabama
Site not named
Tucson, Arizona
Site not named
Tucson, Arizona
Site not named
Little Rock, Arkansas
Site not named
Sherwood, Arkansas
Site not named
Anaheim, California
Site not named
Chula Vista, California
Site not named
Fullerton, California
Site not named
Irvine, California
Site not named
Laguna Hills, California
Site not named
Mission Hills, California
Site not named
Redwood City, California
Site not named
San Diego, California
Site not named
San Louis Obispo, California
Site not named
West Covina, California
Site not named
Pueblo, Colorado
Site not named
Wheat Ridge, Colorado
Site not named
Bristol, Connecticut
Site not named
Hartford, Connecticut
Site not named
Boynton Beach, Florida
Site not named
Hialeah, Florida
Site not named
Hollywood, Florida
Site not named
Jacksonville, Florida
Site not named
Jupiter, Florida
Site not named
Largo, Florida
Site not named
Lauderdale Lakes, Florida
Site not named
Naples, Florida
Site not named
Orlando, Florida
Site not named
Tampa, Florida
Site not named
Tampa, Florida
Site not named
Tampa, Florida
Site not named
Newnan, Georgia
Site not named
Rockford, Illinois
Site not named
Clive, Iowa
Site not named
Kansas City, Kansas
Site not named
Topeka, Kansas
Site not named
Louisville, Kentucky
Site not named
Louisville, Kentucky
Site not named
Baton Rouge, Louisiana
Site not named
Slidell, Louisiana
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.